Nov. 14 at 11:07 PM
$IFRX OPEN AI :
Based on recent licensing deals, a Phase 2 asset like InflaRx's INF904 would have a much higher valuation range than
$BIIB / Vanqua's preclinical asset, typically seeing significantly larger upfront payments and total potential deal values.
Potential "Fair Value" for InflaRx
If a large pharmaceutical company were to license InflaRx's P2 asset (INF904), the market data suggests a "fair value" based on the following:
Upfront Payment Range:
$775 million -
$1 billion
Total Deal Value:
The entire deal, including all potential development, regulatory, and sales milestones, could easily reach several billion dollars, often between
$1.5 billion and
$3 billion, depending on the specific disease area, market potential, and data strength.
De-risking: A Phase 2 asset is considered significantly less risky than a preclinical one, as it has already shown initial safety and efficacy in humans. This stage of development commands a higher valuation from potential partners.
